The association between hospital frailty risk score and adverse inpatient outcomes in older adults with colorectal cancer.

IF 6.8 1区医学 Q1 ONCOLOGY

British Journal of Cancer Pub Date : 2026-05-06 DOI:10.1038/s41416-026-03385-2

Hao-Tsai Cheng, Chen-June Seak, Ching-Yi Cheng, Shu-Wei Huang, Chang-Mu Sung, Tsung-Hsing Chen

{"title":"The association between hospital frailty risk score and adverse inpatient outcomes in older adults with colorectal cancer.","authors":"Hao-Tsai Cheng, Chen-June Seak, Ching-Yi Cheng, Shu-Wei Huang, Chang-Mu Sung, Tsung-Hsing Chen","doi":"10.1038/s41416-026-03385-2","DOIUrl":null,"url":null,"abstract":"Background: Impact of frailty on prognosis in patients with metastatic and non-metastatic colorectal cancer (CRC) was studied.Methods: Patients aged ≥60 years with CRC were identified in Nationwide Inpatient Sample database and analyzed retrospectively. Frailty was defined when Hospital Frailty Risk Score ≥5. Patients were grouped and matched by metastatic status. Logistic and linear regression were used to assess association between frailty and in-hospital outcomes.Results: After matching, 99,017 metastatic and 418,435 non-metastatic CRC were included. Frailty was significantly associated with increased in-hospital mortality (metastatic: OR = 1.10, 95% CI 1.05-1.17; non-metastatic: aOR = 1.05, 95% CI 1.00-1.10), prolonged length of stay (metastatic: OR = 1.30, 95% CI 1.26-1.34; non-metastatic: aOR = 1.37, 95% CI 1.34-1.39), and discharge to long-term care (metastatic: OR = 1.67, 95% CI 1.62-1.73; non-metastatic: aOR = 2.10, 95% CI 2.07-2.14). Frailty was also associated with higher total hospital costs, with additional $3,750 (95% CI $2940-$4560) in metastatic CRC and $1920 (95% CI $1480-$2360) in non-metastatic CRC.Conclusions: Frailty is an independent predictor of adverse outcomes among older patients with CRC, regardless of metastatic status.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41416-026-03385-2","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Impact of frailty on prognosis in patients with metastatic and non-metastatic colorectal cancer (CRC) was studied.

Methods: Patients aged ≥60 years with CRC were identified in Nationwide Inpatient Sample database and analyzed retrospectively. Frailty was defined when Hospital Frailty Risk Score ≥5. Patients were grouped and matched by metastatic status. Logistic and linear regression were used to assess association between frailty and in-hospital outcomes.

Results: After matching, 99,017 metastatic and 418,435 non-metastatic CRC were included. Frailty was significantly associated with increased in-hospital mortality (metastatic: OR = 1.10, 95% CI 1.05-1.17; non-metastatic: aOR = 1.05, 95% CI 1.00-1.10), prolonged length of stay (metastatic: OR = 1.30, 95% CI 1.26-1.34; non-metastatic: aOR = 1.37, 95% CI 1.34-1.39), and discharge to long-term care (metastatic: OR = 1.67, 95% CI 1.62-1.73; non-metastatic: aOR = 2.10, 95% CI 2.07-2.14). Frailty was also associated with higher total hospital costs, with additional $3,750 (95% CI $2940-$4560) in metastatic CRC and $1920 (95% CI $1480-$2360) in non-metastatic CRC.

Conclusions: Frailty is an independent predictor of adverse outcomes among older patients with CRC, regardless of metastatic status.

查看原文本刊更多论文

老年结直肠癌患者住院虚弱风险评分与不良住院预后的关系

背景：研究了虚弱对转移性和非转移性结直肠癌（CRC）患者预后的影响。方法：从全国住院患者样本数据库中选取年龄≥60岁的结直肠癌患者进行回顾性分析。当医院虚弱风险评分≥5分时定义为虚弱。患者按转移状态进行分组和匹配。采用逻辑回归和线性回归来评估虚弱与住院预后之间的关系。结果：配对后，纳入99,017例转移性结直肠癌和418,435例非转移性结直肠癌。虚弱与住院死亡率增加（转移性：OR = 1.10, 95% CI 1.05-1.17；非转移性：aOR = 1.05, 95% CI 1.00-1.10）、住院时间延长（转移性：OR = 1.30, 95% CI 1.26-1.34；非转移性：aOR = 1.37, 95% CI 1.34-1.39）和出院接受长期护理（转移性：OR = 1.67, 95% CI 1.62-1.73；非转移性：aOR = 2.10, 95% CI 2.07-2.14）显著相关。虚弱也与较高的总住院费用相关，转移性CRC患者额外花费3750美元（95% CI 2940- 4560美元），非转移性CRC患者额外花费1920美元（95% CI 1480- 2360美元）。结论：无论转移状态如何，虚弱是老年结直肠癌患者不良结局的独立预测因子。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

British Journal of Cancer 医学-肿瘤学

CiteScore

15.10

自引率

1.10%

发文量

383

审稿时长

6 months

期刊介绍： The British Journal of Cancer is one of the most-cited general cancer journals, publishing significant advances in translational and clinical cancer research.It also publishes high-quality reviews and thought-provoking comment on all aspects of cancer prevention,diagnosis and treatment.